Workflow
SWK Holdings(SWKH)
icon
Search documents
SWK Holdings(SWKH) - 2021 Q2 - Earnings Call Transcript
2021-08-17 23:45
Financial Data and Key Metrics Changes - SWK Holdings reported total revenue of $22.3 million for Q2 2021, a significant increase from $7.9 million in Q2 2020, representing a $14.4 million net increase in revenue [21] - The company achieved a GAAP net income of $14 million or $1.09 per diluted share for Q2 2021, compared to $876,000 or $0.07 per diluted share for the same period in 2020 [24] - The weighted average projected effective yield of the financed receivables portfolio was 13.9% as of June 30, 2021, up from 13.2% a year earlier [18] - Book value per share increased to $20.18, a 12% year-over-year increase from $18.06 [19] Business Line Data and Key Metrics Changes - The financial receivable segment generated a realized yield of 20.9% for Q2 2021, driven by the company's investment strategy focused on small and midsized life science companies [7] - Enteris BioPharma, a subsidiary, reported a $10.3 million increase in revenues primarily due to a license agreement with Cara Therapeutics, which included a $6.1 million payment to the former Enteris owner [22] Market Data and Key Metrics Changes - SWK's portfolio of royalties and structured credit backed by royalties totaled approximately $230 million across 25 partners, a 16.8% increase from $182.3 million in the same period last year [17] Company Strategy and Development Direction - The company continues to focus on niche healthcare specialty finance, funding growth opportunities for small and mid-sized life science companies through unique financing structures [9][10] - A Strategic Review Committee was formed to explore strategic alternatives aimed at maximizing stockholder value, although no decisions have been made yet [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of life science companies from the COVID-19 pandemic and the ongoing demand for capital to fund innovations [8] - The company remains well-positioned to capitalize on compelling investment opportunities in the specialty finance sector [26] Other Important Information - SWK has $32 million of cash and revolver availability to support partner companies and capitalize on potential investment opportunities [12] - The company is actively seeking new transactions that leverage its expertise in the specialty finance business [25] Q&A Session Summary Question: Has the build-out of Enteris operations provided momentum for new partnerships? - Management confirmed that Enteris has signed three new feasibility studies, indicating positive momentum in partnerships [32] Question: What is the current leverage ratio and appetite for more debt? - Management stated there is capacity to support larger credit facilities and that the Strategic Review Committee's recommendations will influence future capital structure decisions [34][35] Question: How is the investment environment compared to six months ago? - Management noted that while the landscape is competitive, there are still ample opportunities, and they expect to close additional deals by year-end [37] Question: Can you provide details on the remaining milestones with Cara? - Management indicated that while specific details are redacted, there are several milestones remaining, typically related to clinical program advancements [40] Question: What is the status of the CDMO business pipeline? - Management reported that the pipeline is building, with interest from potential partners now that the facility is operational [49] Question: What is the timeline for the Strategic Review Committee? - Management did not provide a specific timeline but confirmed that progress is being made [52] Question: How does the royalty payment recognition work for Narcan? - Management clarified that revenue is recognized on royalties in arrears, meaning payments are based on prior quarter sales [72]
SWK Holdings(SWKH) - 2021 Q2 - Quarterly Report
2021-08-16 20:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39184 SWK Holdings Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 77-0435679 Organization) (I.R.S. Employer Identification No.) 14755 Preston Ro ...
SWK Holdings(SWKH) - 2021 Q1 - Quarterly Report
2021-05-17 20:56
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39184 SWK Holdings Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 77-0435679 (State or Other Jurisdiction of Incorporation or Organization) (I. ...
SWK Holdings(SWKH) - 2020 Q4 - Annual Report
2021-03-31 20:45
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39184 SWK HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 77-0435679 (State or Other Jurisdiction of Incorporation or Organizatio ...
SWK Holdings(SWKH) - 2020 Q3 - Quarterly Report
2020-11-13 21:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39184 SWK Holdings Corporation (Exact Name of Registrant as Specified in its Charter) Indicate by check mark whether the registrant has submitted electronically every I ...
SWK Holdings(SWKH) - 2020 Q2 - Earnings Call Transcript
2020-08-18 18:58
SWK Holdings Corporation (NASDAQ:SWKH) Q2 2020 Results Conference Call August 17, 2020 10:00 AM ET Company Participants Jason Rando - Tiberend Strategic Advisors Winston Black - Chairman and CEO Conference Call Participants Kyle Bauser - Colliers Securities Nat Stewart - N.A.S. Capital LLC Operator Good morning. Welcome to SWK Holdings Second Quarter 2020 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions]. After today’s presentation, there will be an ...
SWK Holdings(SWKH) - 2020 Q2 - Quarterly Report
2020-08-14 20:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39184 SWK Holdings Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 77-0435679 (State or Other Jurisdiction of Incorporation or Organization) (I.R ...
SWK Holdings (SWKH) Presemts At Life Sciences Investor Virtual Forum - Slideshow
2020-06-26 20:42
| --- | --- | --- | |---------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | Collaborative Approach to Life Science Financing | | | | Corporate Presentation June 25, 2020 | | | Forward-looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federa ...
SWK Holdings(SWKH) - 2020 Q1 - Quarterly Report
2020-05-14 20:06
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39184 SWK Holdings Corporation (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR Delaware 77-0435679 (State or Other Jurisdiction of Incorporation or Organization) (I. ...
SWK Holdings(SWKH) - 2019 Q4 - Earnings Call Transcript
2020-03-31 18:41
SWK Holdings Corporation (NASDAQ:SWKH) Q4 2019 Earnings Conference Call March 31, 2020 10:00 AM ET Company Participants Jason Rando - Tiberend Strategic Advisors, Inc. Winston Black - Chairman and Chief Executive Officer Conference Call Participants Operator Good day. And welcome to SWK Holdings Corporation Fourth Quarter and Full Year 2019 Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note the event is being recorded. And now I'd like to turn the conference o ...